XML 38 R25.htm IDEA: XBRL DOCUMENT v3.21.1
SEGMENT AND ENTERPRISE-WIDE INFORMATION
 12 Months Ended
Apr. 03, 2021
Segment Reporting [Abstract]  
SEGMENT AND ENTERPRISE-WIDE INFORMATION SEGMENT AND ENTERPRISE-WIDE INFORMATION
The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. Historically, the Company's operating segments were based primarily on geography. Effective as of March 31, 2019, the Company completed the transition of its operating structure to three global business units and accordingly, reorganized its reporting structure to align with its three global business units and the information that will be regularly reviewed by the Company's chief operating decision maker.

Following the reorganization, the Company's reportable segments are as follows:
•Plasma
•Blood Center
•Hospital

Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include restructuring and turnaround costs, deal amortization, gains and losses on dispositions and sale of assets, asset impairments, accelerated device depreciation and related costs, costs related to compliance with the European Union Medical Device Regulation, transaction and integration costs and certain tax settlements and unusual or infrequent and material litigation-related charges. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company's net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis.

Selected information by reportable segment is presented below:
(In thousands)202120202019
Net revenues
Plasma$333,334 $460,637 $426,781 
Blood Center307,370 325,661 335,557 
Hospital210,606 194,604 190,821 
Net revenues by business unit851,310 980,902 953,159 
Service (1)
20,758 19,830 19,906 
Effect of exchange rates(1,605)(12,253)(5,486)
Net revenues$870,463 $988,479 $967,579 
(1) Reflects revenue for service, maintenance and parts.
(In thousands)202120202019
Segment operating income
Plasma$172,463 $225,351 $180,300 
Blood Center141,962 159,802 163,628 
Hospital84,066 80,669 76,338 
Segment operating income398,491 465,822 420,266 
  Corporate expenses (1)
(256,751)(255,727)(263,603)
  Effect of exchange rates12,830 7,920 8,367 
Deal amortization(32,830)(25,746)(24,803)
Impairment of assets, PCS2 accelerated depreciation and other related charges(25,696)(75,750)(40,296)
Transaction and Integration costs(18,421)(568)— 
Restructuring and turnaround costs(15,661)(19,878)(13,660)
European Medical Device Regulation costs and other(4,130)(1,506)— 
Litigation-related charges(897)701 (2,726)
Gains on divestitures and sale of assets32,812 8,083 — 
Operating income$89,747 $103,351 $83,545 
(1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.
(In thousands)202120202019
Depreciation and amortization
Plasma$24,093 $63,347 $61,721 
Blood Center39,672 38,429 38,074 
Hospital20,522 8,513 9,623 
Total depreciation and amortization (excluding impairment charges)$84,287 $110,289 $109,418 

(In thousands)April 3,
2021		March 28,
2020		March 30,
2019
Long-lived assets(1)
Plasma$105,599 $141,903 $192,628 
Blood Center83,225 93,758 127,272 
Hospital28,735 17,738 24,079 
Total long-lived assets$217,559 $253,399 $343,979 
(1) Long-lived assets are comprised of property, plant and equipment.

Selected information by principle operating regions is presented below:
(In thousands)April 3,
2021		March 28,
2020		March 30,
2019
Long-lived assets(1)
United States$159,749 $186,488 $269,849 
Japan1,515 2,037 1,726 
Europe10,384 10,143 11,200 
Asia30,588 29,175 30,930 
Other15,323 25,556 30,274 
Total long-lived assets$217,559 $253,399 $343,979 
(1) Long-lived assets are comprised of property, plant and equipment.
(In thousands)202120202019
United States$522,607 $646,204 $606,845 
Japan77,676 72,218 69,908 
Europe159,077 153,347 164,504 
Asia105,820 109,295 118,700 
Other5,283 7,415 7,622 
Net revenues$870,463 $988,479 $967,579 

Management reviews revenue based on the reportable segments noted above. Although these reportable segments are primarily product-based, they differ from the Company’s product line revenues for Plasma products and services and Blood Center products and services. Specifically, the Blood Center reportable segment includes plasma products utilized for collection in blood centers primarily for transfusion purposes. Additionally, product line revenues also include service revenues which are excluded from the reportable segments.

Net revenues by product line are as follows:
(In thousands)202120202019
Plasma products and services414,266 537,231 501,837 
Blood Center products and services239,614 252,829 269,203 
Hospital products and services216,583 198,419 196,539 
Net revenues$870,463 $988,479 $967,579